Showing results (311-320 of 368) with videos related to
Sort By:
Pageof 37
American Heart Journal|December 7, 2019
Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry programMichał Mazurek, Christine Teutsch, Hans-Christoph Diener, et al.TH Open : Companion Journal to Thrombosis and Haemostasis|February 10, 2021
Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AFSake J van der Wall, Christine Teutsch, Sergio J Dubner, et al.Pharmacotherapy|May 29, 2014
Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort studyJames A Kaye, Jordi Castellsague, Christine L Bui, et al.ESC Heart Failure|July 3, 2020
Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-AFSergio J Dubner, Christine Teutsch, Menno V Huisman, et al.Pharmacoepidemiology and Drug Safety|February 28, 2024
Staging and clean room: Constructs designed to facilitate transparency and reduce bias in comparative analyses of real-world dataPaul Muntner, Rohini K Hernandez, Shia T Kent, et al.Environmental Research|December 29, 2023
Ambient air pollution and rate of spontaneous abortionAmelia K Wesselink, Kipruto Kirwa, Perry Hystad, et al.Vaccine|June 10, 2023
COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort studyAmelia K Wesselink, Sharonda M Lovett, Janice Weinberg, et al.Journal of the American Society of Nephrology : JASN|February 27, 2016
Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment ReformGlenn M Chertow, Jiannong Liu, Keri L Monda, et al.Clinical Epidemiology|March 22, 2018
A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study)Jordi Castellsague, Josephina G Kuiper, Anton Pottegård, et al.Diabetes Care|February 16, 2024
Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort StudyMary S Anthony, Vanita R Aroda, Lauren E Parlett, et al.Pageof 37